Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A minor version label update is shown: Revision: v3.3.2 is now displayed, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:41:35.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    PubMed publications section wording updated to 'automatically filled in from PubMed'. Page revision tag updated to Revision: v3.3.1.
    Difference
    0.3%
    Check dated 2025-11-24T14:50:45.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Two new study sites in Taiwan were added: Tainan, Taiwan, 704 and Tainan, Taiwan, 71004. The previous Tainan City entries for these locations were removed.
    Difference
    0.2%
    Check dated 2025-11-17T07:14:10.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    Visual layout tweaks (spacing and header styling) appear in the screenshots, with no changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:23:27.000Z thumbnail image
  5. Check
    64 days ago
    Change Detected
    Summary
    Updated page to v3.2.0 with a new government-operating-status notice; removed the resource for Differentiated thyroid carcinoma from the Genetic and Rare Diseases Information Center.
    Difference
    3%
    Check dated 2025-10-05T10:36:13.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    The page has been updated to include new dates, a EU Trial CTIS number, revision version, and update indicators, while several historical safety-related sections and older update references were removed. Overall, the changes mainly update metadata and identifiers rather than core content.
    Difference
    1%
    Check dated 2025-09-28T03:27:31.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.